Literature DB >> 8304301

Investigation of resected multinodular hepatocellular carcinoma: assessment of unicentric or multicentric genesis from histological and prognostic viewpoint.

S Nakano1, J Haratake, K Okamoto, S Takeda.   

Abstract

OBJECTIVES: Multicentricity of hepatocellular carcinoma (HCC) is attracting a great deal of attention at present. However, few studies have focused on the prognostic comparison between unicentric and multicentric multinodular HCCs. The aim of this study is the reevaluation of histologic criteria of multicentric HCC and a prognostic comparison between the two groups mentioned above.
METHODS: Forty-nine cases with intrahepatic multiple nodules of HCC, by gross examination, among 184 consecutive resected HCCs were examined clinicopathologically. These cases were divided into three groups: group A, cases suggestive of multicentric genesis; group B, unicentric cases; and group C, indeterminate cases. Histopathological characteristics and the cumulative survival rates were compared among these groups.
RESULTS: Five cases were categorized as group A, 36 cases as group B, and eight cases as group C. Nodules in group A were smaller than 2 cm in diameter, situated discretely and well differentiated, and with neither vascular nor capsular invasion. Most of the nodules lacked a tumor capsule and had an irregular border. In the 36 cases of group B, all main tumors had vascular and/or capsular invasion. The cellularity index was almost the same in all groups. The cumulative survival rate of group A was better than that of group B or group C.
CONCLUSIONS: Small multiple nodules of well-differentiated hepatocellular carcinoma without vascular and capsular invasion might be multicentric, and these early detections and operations could result in a fairly good prognosis, despite the multiple HCC nodules.

Entities:  

Mesh:

Year:  1994        PMID: 8304301

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  7 in total

1.  Expression and significance of new inhibitor of apoptosis protein survivin in hepatocellular carcinoma.

Authors:  Hong Zhu; Xiao-Ping Chen; Wan-Guang Zhang; Shun-Feng Luo; Bi-Xiang Zhang
Journal:  World J Gastroenterol       Date:  2005-07-07       Impact factor: 5.742

2.  Long-Term Survival Outcomes After Liver Resection for Binodular Hepatocellular Carcinoma: A Multicenter Cohort Study.

Authors:  Ming-Da Wang; Chao Li; Jun Li; Wan-Guang Zhang; Wei-Qin Jiang; Jiong-Jie Yu; Hao Xing; Han Wu; Jun Han; Zhen-Li Li; Xin-Fei Xu; Ting-Hao Chen; Ya-Hao Zhou; Wei-Min Gu; Hong Wang; Yong-Yi Zeng; Yao-Ming Zhang; Timothy M Pawlik; Wan Yee Lau; Meng-Chao Wu; Jia-Mei Yang; Feng Shen; Tian Yang
Journal:  Oncologist       Date:  2019-05-24

3.  Clinical value of apoptosis and angiogenesis factors in estimating the prognosis of hepatocellular carcinoma.

Authors:  Rong-Ping Guo; Chong Zhong; Ming Shi; Chang-Qing Zhang; Wei Wei; Ya-Qi Zhang; Jin-Qing Li
Journal:  J Cancer Res Clin Oncol       Date:  2006-06-09       Impact factor: 4.553

Review 4.  Histopathology of hepatocellular carcinoma.

Authors:  Manuel Schlageter; Luigi Maria Terracciano; Salvatore D'Angelo; Paolo Sorrentino
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

5.  Is the expression of gamma-glutamyl transpeptidase messenger RNA an indicator of biological behavior in recurrent hepatocellular carcinoma?

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Yi-Chun Tsai
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

6.  Is p53 gene mutation an indicatior of the biological behaviors of recurrence of hepatocellular carcinoma?

Authors:  I-Shyan Sheen; Kuo-Shyang Jeng; Ju-Yann Wu
Journal:  World J Gastroenterol       Date:  2003-06       Impact factor: 5.742

7.  Clinicopathological criteria for multicentricity of hepatocellular carcinoma and risk factors for such carcinogenesis.

Authors:  S Kubo; S Nishiguchi; K Hirohashi; T Shuto; T Kuroki; S Minamitani; T Ikebe; T Yamamoto; K Wakasa; H Kinoshita
Journal:  Jpn J Cancer Res       Date:  1998-04
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.